Currently, several clinical trials using IDH1/2 inhibitors, such as NCT04056910 (phase II study of IDH1 inhibitor ivosidenib and nivolumab in IDH1‐mutant gliomas and advanced solid tumors), NCT02746081 (phase I study of BAY1436032 in IDH1‐mutant advanced solid tumors), and NCT02481154 (phase I study of orally administered AG‐881 in IDH1/IDH2‐mutant advanced solid tumors), have been conducted to explore the efficacy of these treatments against advanced solid tumors including NSCLC.4 This evidence concerns the gene IDH2 and glioma.